drugset
drugset / Trial / NCT05903118

A Phase I/II Study to Evaluate a SARS-CoV-2 mRNA Vaccine in Healthy Adults

NCT05903118 ↗

Phase 1/2 Completed 480 enrolled Argorna Pharmaceuticals Co., LTD
RandomizedParallel-groupDouble-blindPrevention

Summary

The phase I/II study is to evaluate the safety and immunogenicity of SARS-COV-2 mRNA Vaccine (RBMRNA-176) at different doses in healthy subjects aged 18 years and older.

Timeline

Start
2022-01-08
Primary completion
2022-09-01
Completion
2023-07-19

Drugs

EvaluationDrugModalityDoseRoute
Subject RBMRNA-176 Messenger RNA (mRNA) — Intramuscular

Indications

COVID-19